| 000 | 00869nam a22002057a 4500 | ||
|---|---|---|---|
| 008 | 140213b xxu||||| |||| 00| 0 eng d | ||
| 040 | _cVAD | ||
| 041 | _aEngels | ||
| 110 |
_aEuropean Monitoring Center for Drugs and Drug Addiction [EMCDDA] _947393 |
||
| 245 | _aADB-CHMINACA : Report on the risk assessment of N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) in the framework of the Council Decision on new psychoactive substances [PDF] | ||
| 260 |
_aLisbon _bEMCDDA _c2018 |
||
| 300 | _a83 p. | ||
| 490 |
_aRisk assessments _v22 |
||
| 650 | _adrugs | ||
| 650 | _aNieuwe Psychoactieve Stoffen | ||
| 650 | _aproductinformatie | ||
| 650 | _aonderzoeksrapporten | ||
| 650 | _arisicoschatting | ||
| 856 | _uhttp://www.google.com/search?q=Report-on-the-risk-assessment-of-N-1-amino-3-3dimethyl-1-oxobutan-2-yl | ||
| 999 |
_c19721 _d19721 |
||